Inhibikase Therapeutics Inc. (NASDAQ: IKT) Stock Information | RedChip

Inhibikase Therapeutics Inc. (NASDAQ: IKT) Listen to this Section


$1.27
+0.0350 ( +2.85% ) 7.6K

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Market Data


Open


$1.27

Previous close


$1.23

Volume


7.6K

Market cap


$9.16M

Day range


$1.22 - $1.36

52 week range


$0.79 - $3.82

Insider Ownership Transactions

Total Amount Purchased: 0.00 | $ 0.00

Date Type Amount Purchased Purchaser
No records found.

SEC Fillings


Form Type Description Pages Date
10-q Quarterly Reports 62 May 15, 2024
8-k 8K-related 39 Apr 30, 2024
ars Annual reports 1 Apr 26, 2024
def Proxies and info statements 3 Apr 26, 2024
8-k 8K-related 15 Apr 19, 2024
pre Proxies and info statements 3 Apr 15, 2024
4 Insider transactions 1 Apr 03, 2024
4 Insider transactions 1 Apr 02, 2024
8-k/a 8K-related 14 Apr 02, 2024
3 Insider transactions 1 Apr 02, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.